Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MDM4 | O15151 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16503525 | 0.89 | CYP26A1 (0.34) | POLBRAB9AL3MBTL1 | |
| SCHEMBL16900479 | 0.88 | NPSR1 (0.39) | POLBRAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL16503532 | 0.86 | CCNC (0.38) | KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL16503531 | 0.84 | CA2 (0.31) | — | |
| SCHEMBL16900478 | 0.83 | BACE1 (0.34) | POLBKMT2AKDM4ELMNABACE1 | |
| SCHEMBL16503521 | 0.83 | POLB (0.33) | POLBRAB9AKMT2AKDM4EMAPT | |
| SCHEMBL16503519 | 0.79 | BACE1 (0.32) | BACE1 | |
| SCHEMBL16503520 | 0.79 | KMT2A (0.39) | RAB9AKMT2AKDM4ESMN1; SMN2BACE1 | |
| SCHEMBL20640547 | 0.78 | CA2 (0.34) | KMT2AMAPTLMNAATML3MBTL1 | |
| SCHEMBL16503530 | 0.78 | RECQL (0.34) | POLBRAB9AKMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403842-B1 | CHIRAL DISULFONIMIDES | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| US-9079869-B2 | Chiral disulfonimides | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-9079869-B2 | Chiral disulfonimides | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-20110313150-A1 | CHIRAL DISULFONIMIDES | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313150-A1 | CHIRAL DISULFONIMIDES | STS, SUDS3, SF1 | POLB 3476/4885RAB9A 1666/4885KMT2A 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.